Medicines that matter.
Markets others may overlook.
STAK Pharma focuses on medicines where there is a demonstrated Canadian need but limited commercial attention. We believe the importance of a medicine should not be defined solely by the size of its market.
Our focus includes established medicines, orphan generics, ultra-niche molecules, products vulnerable to discontinuation, and medicines requiring a dedicated Canadian commercialization partner.
Our focus
Orphan & Niche Medicines
Medicines serving small or highly specialized patient populations where traditional commercial models may be challenging.
Established Medicines
Clinically important, mature molecules that continue to play an essential role in patient care.
Supply-Vulnerable Products
Medicines affected by discontinuations, limited suppliers or other factors that can put reliable Canadian access at risk.
Canadian Market Opportunities
Internationally available medicines with demonstrated Canadian need that require a knowledgeable local partner.
Our approach
Assess Canadian clinical need and market opportunity.
Analyze feasibility, demand and pathway options.
Work with trusted international manufacturers and partners.
Manage regulatory, market access and supply considerations.
Support long-term availability for Canadian patients.
From global manufacturer
to Canadian patient.
STAK combines pharmaceutical, regulatory and health-system expertise to evaluate whether an important medicine can be sustainably brought to—or maintained in—the Canadian market.
We work with established international manufacturers and pharmaceutical partners to develop practical Canadian pathways while maintaining a focus on quality, regulatory compliance and continuity of supply.
What we look for
- Demonstrated clinical need
- Limited Canadian availability
- Sustainable manufacturing
- Feasible regulatory pathway
- Opportunity for long-term supply
Partner with STAK
Have a product that could fill an unmet need in Canada? Whether you're an international manufacturer, a pharmaceutical company reconsidering a mature product, or an organization that has identified an unmet medication need, we'd like to hear from you.
Discuss an opportunity →